GLP-1 Inhibitor Reduces Knee Osteoarthritis Pain Save Semaglutide (Wegovy) reduced pain and improved physical function in patients with obesity and knee osteoarthritis, a randomized trial showed
Provider Comparison now adds practical 2026 context for Provider Comparison, Provider Comparison tool, GLP-1 planning, peptide therapy, dosing, cost, safety, patient tracking, and 2026 treatment decisions, and related searches such as provider, comparison, tool, glp-1, planning, peptide, therapy, dosing
Slight variations in injection site or angle determine whether you avoid or encounter these structures
Second, the rapid fat loss driven by potent GLP-1-class agents releases sequestered vitamin D from adipose stores but also accelerates bone remodeling, which changes how the body uses calcium and vitamin D over time
Osteoarthritis The STEP 9 trial of 407 participants with a clinical and radiologic diagnosis of moderate knee osteoarthritis who had at least moderate pain and BMI 30 reported that semaglutide 2.4 mg weekly over 68 weeks improved the WOMAC pain score (range 0100, with a higher score indicating more pain) by 41.7 points compared to 27.5 points with placebo (CI 95%